Bio Green Med Solution Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed quorum and approved all proposals, including director elections, auditor ratification, and executive compensation. Shareholders participated virtually, with a Q&A session and follow-up promised for unanswered questions.
Fiscal Year 2024
-
FADRA, a dual CDK2/9 inhibitor, is showing promising efficacy and safety in phase 2 trials for cancers with CDKN2A/B mutations and T-cell lymphoma, with durable responses and strong biomarker rationale. PLOGO, a PLK-1 inhibitor, is being reformulated for future trials targeting ARID1A or TP53 mutations.
-
Phase 2 enrollment for Fadraciclib is progressing, with initial data from about 12 patients expected by year-end 2024. Cash resources are projected to last into Q4 2024, and R&D expenses have decreased year-over-year.